109 related articles for article (PubMed ID: 22161982)
21. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
Gunningham SP; Currie MJ; Han C; Robinson BA; Scott PA; Harris AL; Fox SB
Clin Cancer Res; 2000 Nov; 6(11):4278-86. PubMed ID: 11106244
[TBL] [Abstract][Full Text] [Related]
22. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model.
Yoshimoto M; Kinuya S; Kawashima A; Nishii R; Yokoyama K; Kawai K
Nucl Med Biol; 2006 Nov; 33(8):963-9. PubMed ID: 17127168
[TBL] [Abstract][Full Text] [Related]
23. VEGF as a key mediator of angiogenesis in cancer.
Carmeliet P
Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy.
Zhang X; Bao S; Hambly BD; Gillies MC
Int J Biochem Cell Biol; 2009 Dec; 41(12):2368-71. PubMed ID: 19646547
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
27. Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors.
Hara H; Akisue T; Fujimoto T; Imabori M; Kawamoto T; Kuroda R; Fujioka H; Yamamoto T; Doita M; Kurosaka M
Anticancer Res; 2006; 26(6B):4307-11. PubMed ID: 17201149
[TBL] [Abstract][Full Text] [Related]
28. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical localization of vascular endothelial growth factor (VEGF) and its two specific receptors, Flt-1 and KDR, in the porcine placenta and non-pregnant uterus.
Winther H; Ahmed A; Dantzer V
Placenta; 1999 Jan; 20(1):35-43. PubMed ID: 9950143
[TBL] [Abstract][Full Text] [Related]
30. [Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma].
Wang H; Chen G; Zhang B
Zhonghua Bing Li Xue Za Zhi; 2002 Oct; 31(5):391-5. PubMed ID: 12485477
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA
Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor in thyroid cancers.
Lin JD; Chao TC
Cancer Biother Radiopharm; 2005 Dec; 20(6):648-61. PubMed ID: 16398617
[TBL] [Abstract][Full Text] [Related]
35. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.
Dvorak HF
Cancer J; 2015; 21(4):237-43. PubMed ID: 26222073
[TBL] [Abstract][Full Text] [Related]
36. [Intraocular antiangiogenic drugs in clinical application advantages and disadvantages].
Li XX
Zhonghua Yan Ke Za Zhi; 2012 Oct; 48(10):870-3. PubMed ID: 23302238
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic therapy for diabetic retinopathy.
Gardlik R; Fusekova I
Semin Ophthalmol; 2015 Jul; 30(4):252-63. PubMed ID: 24571780
[TBL] [Abstract][Full Text] [Related]
38. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
39. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
40. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
